Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

hGH-CTP

- PMLiVE

Shionogi starts phase 2 clinical trial for Pompe Disease

The rare disease affects around one in every 22,000 people worldwide

Site Factor report illustrations

Why patient-centricity depends on site-centricity in clinical trials

Explore why patient-centricity in clinical trials relies on site-centricity, emphasising the need to design trials that empower site teams to better support patients.

Cuttsy + Cuttsy

Before and after

From cloudy to clear: visualising complex data privacy information

Discover how clear communication principles can transform complex clinical research topics, as we conclude our Health Literacy series with a practical example on participant data transparency.

Cuttsy + Cuttsy

Carer with patient

The invisible influence on trial retention: why caregivers must be part of the plan

Caregivers are vital to clinical trial retention, yet often overlooked—this article highlights their challenges, impact, and how to better support them.

Cuttsy + Cuttsy

The Site Factor - printed report

Where it all began: why we wrote ‘The Site Factor’

Discover the story behind ‘The Site Factor’ and how understanding site teams’ experiences can transform clinical trials for participants and researchers alike.

Cuttsy + Cuttsy

- PMLiVE

Novo Nordisk’s Awiqli approved by US FDA as once-weekly basal insulin for patients with type 2 diabetes

The insulin is designed as an alternative to daily basal insulin

- PMLiVE

Lundbeck completes patient randomisation for phase 3 trial for multiple system atrophy treatment

The rare neurodegenerative disorder has no cure and no approved treatments

- PMLiVE

Novo Nordisk elects employee representatives to Board of Directors

The elected employee representatives will join the Board of Directors after the annual general meeting on 26 March 2026

- PMLiVE

Novo Nordisk to invest 432m euros to expand manufacturing facility in Ireland

Construction is expected to be completed in phases from the end of 2027 into 2028

- PMLiVE

Novo Nordisk and Vivtex partner in deal worth up to $2.1bn

The companies aim to develop next-generation oral medicines for obesity and diabetes

- PMLiVE

Novo Nordisk to lower list price, or wholesale acquisition cost, for Wegovy and Ozempic

The reduction in price to $675 will take effect at the beginning of next year

phthalmologist, optometrist checking child, little girl vision looking for problems and caring for eye

Why patient engagement must come first in rare disease trials

Explore why patient engagement is the cornerstone of successful rare disease trials, emphasising the importance of designing studies around the realities of patients' lives to build trust and improve outcomes.

Cuttsy + Cuttsy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links